




Kingdom of Saudi Arabia
 Ministry of Higher Education
 King Faisal University
College of Clinical Pharmacy



Name	Dr. Maitham Abdullah Al Hawaj		
Specialization	Pharmacotherapy		
Current Position	Assistant Professor		
Contact email (Official)	hawaj@kfu.edu.sa		
Alternate email	IP Phone :	0135817175	
Academic Qualifications	Degree/year/university/country	Ph. D, 2012, Virginia Commonwealth University School of Pharmacy Department of Pharmacotherapy and Outcomes Science, Richmond, Virginia, USA	
	Degree/year/university/country	B. Pharmacy, 2005, King Saud University, College of Pharmacy, Riyadh, Saudi Arabia	
	Degree/year/university/country		
Teaching Experience	➤		
	➤	2012–Present, Assistant Professor, Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Hofuf, Saudi Arabia.	
	➤	2008–2009, Preparing Future Faculty Program, Graduate School, Virginia Commonwealth University, Richmond, Virginia, United States.	
All the Courses Taught and Teaching in KFU with Course number	➤	2005–2007, Teaching assistant, Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Hofuf, Saudi Arabia	
	➤	2020111 :Physiology-1	
	➤	2020211 Pathophysiology	
	➤	2030311 Therapeutics-1	
	➤	2030412 Therapeutics-3	
➤	2003521 Therapeutics-4 (old curriculum)		

Research Interests

- Drugs for Thrombotic and Non-Thrombotic Disorders

Publications
(Latest 20
publications)

1. **Al Hawaj MA**, Martin EJ, Venitz J, Barrett JC, Kuhn JG, Nolte ME, Brophy DF. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia. 2013;19(3):409–14.

Presentations and Abstracts

1. **Al Hawaj MA**, Martin E, Barrett JC, Kuhn J, Nolte ME, Brophy DF. Characterizing global hemostasis throughout the FVIII prophylaxis dosing interval: a pilot study. XXX International Congress of the World Federation of Hemophilia; 2012 July 9; Paris, France.
 2. **Al Hawaj MA**, Martin E, Venitz J, Barrett JC, Kuhn J, Nolte ME, Brophy DF. Pharmacokinetic-pharmacodynamic (PK/PD) modeling of factor VIII using its plasma concentration and global hemostasis biomarkers. XXX International Congress of the World Federation of Hemophilia; 2012 July 9; Paris France.
-